Literature DB >> 27105281

Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation.

Ting-Ting Chu1, Na Gao1, Qian-Qian Li1, Pu-Guang Chen1, Xi-Fei Yang2, Yong-Xiang Chen3, Yu-Fen Zhao1, Yan-Mei Li4.   

Abstract

Tau, an important pathological protein of Alzheimer's disease (AD), can mediate the toxicity of amyloid β (Aβ). Thus, reduction of Tau with chemical molecules may offer a novel strategy for treating AD. Here, we designed and synthesized a series of multifunctional molecules that contained Tau-recognition moieties and E3 ligase-binding moieties to enhance Tau degradation. Among these molecules, TH006 had the highest activity of inducing Tau degradation by increasing its poly-ubiquitination. The decrement in Tau induced by TH006 could decrease the cytotoxicity caused by Aβ. Furthermore, TH006 could regulate the Tau level in the brain of an AD mouse model. Therefore, partial reduction of Tau with such multifunctional peptides may open up a novel therapeutic strategy for AD treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27105281     DOI: 10.1016/j.chembiol.2016.02.016

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  43 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 3.  Tau Protein Squired by Molecular Chaperones During Alzheimer's Disease.

Authors:  Nalini Vijay Gorantla; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-09-28       Impact factor: 3.444

Review 4.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 5.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

6.  Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.

Authors:  Jian-Lan Gu; Fei Liu
Journal:  Curr Med Sci       Date:  2021-01-11

Review 7.  Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Authors:  Philipp M Cromm; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

8.  Cyclodextrin-Based Peptide Self-Assemblies (Spds) That Enhance Peptide-Based Fluorescence Imaging and Antimicrobial Efficacy.

Authors:  Jin-Biao Jiao; Guan-Zhen Wang; Xi-Le Hu; Yi Zang; Stéphane Maisonneuve; Adam C Sedgwick; Jonathan L Sessler; Juan Xie; Jia Li; Xiao-Peng He; He Tian
Journal:  J Am Chem Soc       Date:  2020-01-13       Impact factor: 15.419

Review 9.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

Review 10.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.